Catabasis Pharmaceuticals Inc., of Cambridge, Mass., said phase I data published in The Journal of Clinical Pharmacology showed that edasalonexent (CAT-1004), an oral inhibitor of NF-kB, was safe, well-tolerated and inhibited activated NF-kB in adult subjects with Duchenne muscular dystrophy (DMD). Read More
Ethypharm SA, of Saint-Cloud, France, signed a definitive agreement to acquire Martindale Pharma, of Wooburn Green, U.K., which specializes in the fields of opioid addiction, emergency care and sterile injectables. Read More
Zynerba Pharmaceuticals Inc., of Devon, Pa., said it priced a public offering of 2.8 million shares of common stock at $18 per share for gross proceeds of $50.4 million. Read More
The NIH has finalized the Common Rule for human subject protections in federally funded research, stripping away a provision in the draft rewrite of the common rule that would have required researchers to obtain consent to use non-identified tissue specimens. Read More
The FDA still has a ways to go to ensure the safety and quality of the U.S. drug supply chain, as it has yet to inspect nearly 1,000 foreign plants that manufacture drug substances for the market. Read More
DUBLIN – Octimet Oncology NV, a spinout from the Janssen Pharmaceutica NV arm of Johnson & Johnson, raised €11.3 million (US$12 million) in a series A round for clinical development of a drug that hits c-Met (cellular mesenchymal-epithelial transition factor), a receptor tyrosine kinase that is one of the most beguiling targets in cancer. Read More
Tumor heterogeneity, the diverging evolution of both different subparts of primary tumors and of metastases compared to the primary tumor, is often named among the challenges for targeted treatment. Read More
Dermira Inc.’s third positive phase III trial with Cimzia (certolizumab pegol) in moderate to severe psoriasis turned up “market-leading type” results at the 400-mg dose, the firm’s chief development officer, Luis Peña, told BioWorld Today, and enables a regulatory filing in Europe. Read More
The acquisition of two partner-ready nanoparticle cancer candidates developed by Azaya Therapeutics Inc. and an associated nanotech platform could yield potential near-term revenue for Cytori Therapeutics Inc. as well as further-afield promise in the use of Azaya’s nanoparticle liposomal technology for the delivery of targeted regenerative therapies to sites of acute or chronic injury, the company said. Read More
